Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab

Eric Morand et al. published in Annals of the Rheumatic Diseases.

Read article here.